Results from a randomized, double-blinded, placebo-controlled clinical trial carried out in women with PCOS (n = 56, age 18–40 years) receiving melatonin for twelve weeks, demonstrated a decrease in hirsutism and testosterone, as well as in oxidative stress markers, such as malondialdehyde, high sensitivity C reactive protein (hs-CRP), and gene expression of inflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α), were reported, together with the elevation of reduced glutathione (GSH) levels and total antioxidant capacity [46]. This evidence concerns the gene TNF and polycystic ovary syndrome.